Genetic Leap and Lilly Enter Collaboration to Accelerate Genetic Medicine Development with AI
09/05/24, 1:31 PM
Location
Money
$409 million
Industry
artificial intelligence
biotechnology
health care
Type
partnership
Genetic Leap and Eli Lilly and Company have entered a research collaboration to develop genetic medicine therapeutics using Genetic Leap's RNA-targeted AI platform. The collaboration aims to generate oligonucleotide drugs against targets selected by Lilly in high priority therapeutic areas, leveraging the potential of RNA in addressing critical diseases that traditional drugs have not effectively targeted.